Brief: Olema Oncology, Aurigene Announce Exclusive Collaboration, License Agreement To Discover And Develop Novel Cancer Therapies

Olema Pharmaceuticals

09/06/2022 13:06

June 9 (Reuters) - Olema Pharmaceuticals Inc  OLMA.O :
    * OLEMA ONCOLOGY AND AURIGENE ANNOUNCE EXCLUSIVE
COLLABORATION AND
LICENSE AGREEMENT TO DISCOVER AND DEVELOP NOVEL CANCER THERAPIES
    * OLEMA PHARMACEUTICALS INC - OLEMA WILL MAKE AN UPFRONT
LICENSING
PAYMENT OF $8 MILLION FOR RIGHTS TO A PRE-EXISTING AURIGENE
PROGRAM
    * OLEMA PHARMACEUTICALS INC - AURIGENE WILL BE ELIGIBLE FOR
UP TO
$60 MILLION IN POTENTIAL CLINICAL DEVELOPMENT AND REGULATORY
MILESTONES
    * OLEMA PHARMACEUTICALS INC -  AURIGENE WILL BE ELIGIBLE FOR
UP TO
$370 MILLION IN POTENTIAL COMMERCIAL MILESTONES
    * OLEMA PHARMACEUTICALS INC -  AURIGENE WILL BE ELIGIBLE FOR
ROYALTIES RANGING FROM MID-SINGLE DIGITS TO LOW DOUBLE DIGITS
BASED ON ANNUAL NET SALES
    * OLEMA PHARMACEUTICALS INC - DURING RESEARCH TERM, OLEMA
WILL
CONTRIBUTE FUNDING TO AURIGENE TO FACILITATE ONGOING DISCOVERY
EFFORTS
    * OLEMA PHARMACEUTICALS INC - CONTINUES TO BE WELL
CAPITALIZED
WITH SUFFICIENT CASH TO FUND PLANNED RESEARCH AND DEVELOPMENT
OPERATIONS INTO SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX67rr5n 
Further company coverage:  OLMA.O 

 ((reuters.briefs@thomsonreuters.com;))